Article: Nicotinamide Riboside Supplementation Reduces Inflammatory Markers in Immune Cells from Healthy Subjects and Psoriasis Patients: Clinical Findings

Autoimmune Disease Clinical Immune Health Inflammation

Nicotinamide Riboside Supplementation Reduces Inflammatory Markers in Immune Cells from Healthy Subjects and Psoriasis Patients: Clinical Findings

Objectives

To examine how ex-vivo NR supplementation affects adaptive immunity in CD4+ T cells extracted from healthy subjects and those with mild-moderate psoriasis, and to investigate the in vivo effects of oral NR supplementation in healthy volunteers on immune responsiveness.

Journal

Cell Reports Medicine

Key Outcomes

Ex Vivo:

NAD+/NADH ratio was reduced in psoriatic T cells compared to cells from healthy subjects.
NR treatment reduced immune responsiveness in CD4+ T cells from healthy subjects and psoriasis patients.

In Vivo:

NR supplementation replicated the immune-modulating effects observed with ex-vivo NR administration, resulting in a decrease in inflammatory markers while enhancing antioxidant gene expression in immune cells.

Duration

1 week

Dose

1000 mg

Study Design

Ex Vivo:
CD4+ T cells were extracted from 12 mild-moderate psoriasis patients and healthy subjects and then treated with NR

In Vivo:
Randomized, double-blind, placebo-controlled, pilot study in 25 young, healthy subjects

See Published Study

Clinical

Nicotinamide Riboside Supplementation Increases Brain NAD+ Levels in Humans: Clinical Findings

Objectives To investigate the effects of acute NR supplementation on cerebral NAD+ levels in the healthy human brain using a specialized MRI technique called downfield proton magnetic resonance sp...